文献速递精神分裂症与精神病性障碍

抗抑郁药增效氯氮平的真实世界有效性:两项欧洲全国队列的自身对照研究

Real-world effectiveness of clozapine augmentation with antidepressants: within-subject data evidence from two European nationwide cohorts.
PubMed 文献 · Lancet Psychiatry · 2025-01-01

结果显示舍曲林、度洛西汀和艾司西酞普兰增效与精神分裂症复发风险降低相关,标准剂量时风险最低,且低或标准剂量不增加躯体住院风险,高剂量时风险增加但多不显著。

要点

  • 舍曲林、度洛西汀和艾司西酞普兰增效氯氮平与复发风险降低相关。
  • 标准剂量舍曲林30-54 mg/日、艾司西酞普兰6-10 mg/日、度洛西汀18-32 mg/日时复发风险最低。
  • 低或标准剂量抗抑郁药不增加躯体住院风险,高剂量时风险增加但多不显著。

核心结论

  • SSRI和SNRI类抗抑郁药标准剂量增效氯氮平与治疗抵抗性精神分裂症患者复发风险显著降低相关,其他抗抑郁药未见此关联。
  • 抗抑郁药增效的潜在获益需与高剂量时可能的不良躯体结局风险相权衡。

研究设计与样本

  • 自身对照数据证据研究,分析芬兰(1996-2017)和瑞典(2006-23)两项全国队列登记数据后行荟萃分析。
  • 比较特定抗抑郁药增效氯氮平与单用氯氮平,主要结局为精神分裂症复发(ICD-10 F20-F29诊断的住院),次要结局为躯体住院。

主要发现

  • 低或标准剂量抗抑郁药均未与躯体住院风险增加相关,高剂量使用与风险增加相关,但多数风险估计不显著。

关键数值与推荐

  • 主要结局复发风险以调整风险比(aHR)表示,采用自身对照设计评估。

临床怎么用

  • 对氯氮平治疗抵抗性精神分裂症患者,可考虑舍曲林、度洛西汀或艾司西酞普兰标准剂量增效以降低复发风险。
  • 使用抗抑郁药增效时应避免高剂量,以平衡复发获益与潜在躯体不良结局风险。

局限性

  • ethnicity数据不可用。
  • 未纳入有生活经验者参与研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Only 40% of people with treatment-resistant schizophrenia will have an adequate response to clozapine. Data on the effect of antidepressant augmentation on these patients are scarce. We aimed to study the effectiveness and safety of antidepressant augmentations to clozapine in two nationwide cohorts. METHODS: For this within-subject data evidence study, data from two cohort studies were analysed then meta-analysed, including patients with schizophrenia using clozapine identified from Finnish (1996-2017) and Swedish (2006-23) nationwide registers, followed up from first clozapine use until death or end of data linkage. Clozapine augmentation with specific antidepressants was compared with clozapine use only. The primary outcome was schizophrenia relapse (hospital admission with ICD-10 F20-F29 diagnosis), and the secondary outcome was somatic hospital admission. The risk of outcomes (expressed as adjusted hazard ratio [aHR]) was assessed by a within-individual cohort design, using each individual as their own control. Ethnicity data were not available. People with lived experience were not involved. FINDINGS: The analysis included 23 206 clozapine users (9531 women and 13 675 men), with a mean age of 41·3 years (SD 13·5). The lowest risk of relapse was observed for sertraline (meta-analysis aHR 0·76 [95% CI 0·69-0·83]), duloxetine (aHR 0·78 [0·68-0·89]), and escitalopram (0·85 [0·79-0·92]). When antidepressants were recategorised by dose, the lowest risk of relapse was observed for standard doses of sertraline at 30-54 mg/day (aHR 0·49 [0·27-0·89]), escitalopram 6-10 mg/day (aHR 0·57 [0·37-0·88]), and duloxetine 18-32 mg/day (aHR 0·59 [0·46-0·75]). No antidepressant was associated with an increased risk of somatic hospital admission at low or standard dose, whereas high-dose use was associated with increased risk, although most of the risk estimates were not significant. INTERPRETATION: This meta-analysis from two nationwide cohorts indicates that SSRI and SNRI augmentation therapies for people with treatment-resistant schizophrenia are associated with a substantially decreased risk of relapse at standard dose, unlike other antidepressants. Potential benefits associated with augmentation must be balanced against risks of possible deleterious somatic outcomes, which were observed only when antidepressants were used at high doses. FUNDING: Sigrid Jusélius Foundation.

来源:Lancet Psychiatry,查看原文。版权归原作者所有。

引用

  1. Taipale H, Siskind D, Tanskanen A, et al. Real-world effectiveness of clozapine augmentation with antidepressants: within-subject data evidence from two European nationwide cohorts. Lancet Psychiatry. 2025. PMID: 40675714. doi:10.1016/S2215-0366(25)00163-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。